upgrad buy pt broader market sell-off
strong balanc sheet sever discount asset
opportun buy globu long-term vision
share high
believ time come go long share trade market cap
equal excelsiusgp first launch essenti discount
entireti gmed addit invest past year weve held
view spinal robot lag robot market soft-tissu
joint recon estimate gmed instal base approach unit reach
scale implant pull-through support sizabl hardwar growth fulli
acknowledg number must reset uncertainti hamper
near-term rebound spine procedur see impact elect
procedur suspend even back multipl week lost rev
see asset still grow ep low doubl digit procedur
shift outward spoke gmed chairman david paul nass
meet came away believ mr paul want continu expand
focu musculoskelet solut ultim develop
broader musculoskelet compani feel prior valuat level accur
reflect compani transitori period would see depress margin
invest made continu see undergo margin
pressur progress transit today level investor
opportun buy vision much reason price margin
pressur asid still possess oper profil much stronger
peer like bottom cash debt
recent announc stock repurchas program believ gmed balanc
sheet give shelter spine volum may see disrupt
may even use strength balanc sheet acquir asset depress level
type market believ investor would see sign strength
larg valuat call fundament solid gmed
spinal hardwar segment absent grown spine
busi consist peer driven increas global sale forc
draw excelsiusgp sale rep addit continu forev
gmed sale forc still well larger peer buy
pt expect continu hire allow continu peer
spine growth addit excelsiu continu grow particularli
regulatori approv japan new indic interbodi modul
late launch cranial applic submit approv fda
expect compel valu offer hospit site even capit
investor long-term horizon transit broader
musculoskelet compani take time take comfort fact
pure-play spine compani held best rel ihi
across numer valuat metric management guid ep growth
grow in-lin revenu growth would expect meaning leverag take
place beyond invest new program begin wane gmed
profit profil take
valuat rate buy pt base split valuat
ev/ebitda price-to-earnings risk discuss
idc btig estim compani document
million except per share amount
share pull back past two week think time come go long current
market cap essenti equival compani either robot trauma program believ
investor opportun step share current level purchas compani grow multipl
spine market reciev burgeon program robot trauma essenti free
investor long-term invest horizon present diversifi musculoskelet asset peer
margin strong balanc sheet
expect launch interbodi indic excelsiu
potenti approv imag system
potenti launch cranial indic excelsiu
potenti launch robot joint replac system
base case scenario call revenu
emerg revenu forecast ep adj
ebitda margin compar guid amount
adjust estim reflect estim impact covid-
upsid scenario would larg driven increas sale new
excelsiusgp system rapid uptak trauma portfolio
addit top-line revenu could seen rapid resolut
biolog suppli issu rapid integr japanes management team
lower expens would also benefit addit rapid resolut
downsid scenario base case similarli center lower system
sale excelsiusgp slower expect growth trauma persist
issu market biolog would also weigh would
elev expens around product develop launch prolong
impact would also weigh share
globu medic medic devic
compani focus develop
commerci product
promot heal patient
musculoskelet disord
sinc globu incept
compani launch
product offer
spinal care market
compani primarili focus
spinal care recent globu
develop new technolog
product robot surgic
navig well orthoped
essenti remov week revenu assum next month would see lost
revenu equat also reduc excelsiusgp sale
hospit busi purchas capit shift spinal hardwar revenu
balanc excelsiusgp assum portion lost
sale made think capit sale proceed slowli like lower previou
assumpt beyond ad back addit cost believ could
pull back futur invest program necessari off-set dilut margin impact lost revenu
fulli acknowledg difficult exercis point level assum think analysi
point situat weaken revenu estim continu come
btig research estim compani filingsnewold chang
incom etot y/i sale time oper incom incom tax expens net incom share gaap net incom oper expens btig research estim compani report
revenu einnov growthinnov growthmusculoskelet splitmusculoskelet btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
